diaDexus, Inc. Appoints Ralf Schoenbrunner to Senior Vice President, Research and Early Development

  diaDexus, Inc. Appoints Ralf Schoenbrunner to Senior Vice President,
  Research and Early Development

Business Wire

SOUTH SAN FRANCISCO, Calif. -- August 22, 2013

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing
proprietary cardiovascular diagnostic products, today announced that E. Ralf
Schoenbrunner, Ph.D. has been appointed to the position of senior vice
president of research and early development. Dr. Schoenbrunner has more than
20 years of experience in the medical device and diagnostic field including
executing multiple successful product development projects.

“Dr. Schoenbrunner has a proven track record of increasing innovation and
productivity within diagnostic companies by planning and directing all aspects
of the organization’s research and development initiatives,” said Brian Ward,
Ph.D., diaDexus’ president and chief executive officer. “He will play a
critical role on our team as we identify and develop our product pipeline

Most recently, Dr. Schoenbrunner was the vice president of research and
development, molecular diagnostics for Life Technologies Corporation, a global
biotechnology tools company where he helped to build R&D capabilities for IVD
diagnostics. Dr. Schoenbrunner came to Life Technologies Corporation in 2010
as a key employee through the acquisition of AcroMetrix where he was the vice
president of research and development. During his tenure at AcroMetrix, a
privately held company and world market leader for nucleic acid testing
quality and control materials, the company launched 30 new products. From 1992
to 2006, Dr. Schoenbrunner held various positions in the research department
at Roche Diagnostics in Switzerland and Roche Molecular Systems Inc. in
California, both world market leaders in diagnostics. Dr. Schoenbrunner was
amongst others responsible for the development of a fully automated
anti-HIV-1/2 assay and development of the first COBAS TaqMan HIV-1 Test. He
studied at University of Regensburg where he got his Master of Science and
also at the University of Edinburgh. He received his Ph.D. in Physical
Biochemistry from the University of Bayreuth in Germany.

“It’s an exciting time to join the diaDexus team as they execute on the goal
of creating a robust product pipeline,” Dr. Schoenbrunner said. “I look
forward to being an active part of the team that identifies, develops and
commercializes new cardiovascular products.”

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, develops and
commercializes proprietary cardiovascular diagnostic products addressing unmet
needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the
only blood test cleared by the FDA to aid in predicting risk for both coronary
heart disease and ischemic stroke associated with atherosclerosis, the #1 and
#3 causes of death, respectively, in the United States. The company's PLAC®
Test for Lp-PLA[2] Activity, a CE-marked test, is an indicator of
atherosclerotic cardiovascular disease, the #1 cause of death in Europe.
diaDexus is ISO 13485 certified and is manufacturing the PLAC Test for
Lp-PLA[2] Activity on-site. For more information, please visit the company's
website at www.diaDexus.com.


diaDexus, Inc.
Brian E. Ward, Ph.D., 650-246-6400
Jean-Frédéric Viret, Ph.D., 650-246-6400
Media and Investors:
Joey Fleury, 415-946-1090
Press spacebar to pause and continue. Press esc to stop.